• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Sebacia raises $36m for microparticle acne treatment

July 25, 2017 By Sarah Faulkner

SebaciaPrivately-held Sebacia Inc. said today that it closed a $20 million Series D financing round, led by existing investors Versant Ventures, Domain Associates, Accuitive Medical Ventures and Partners Healthcare Innovation Fund.

New investors, including Salem Partners, also joined the round. The Duluth, Ga.-based company also said it closed a $16 million debt facility with Hercules Capital.

The company plans to use the funds to finish a pivotal trial in the U.S. of its microparticle acne treatment. Sebacia said it expects results from the study in mid-2018.

“At this pivotal time, we are grateful for the continued support of our top-tier venture capital syndicate and energized by the addition of Salem Partners and other new investors,” CEO Anthony Lando said in prepared remarks. “From intellectual property to extensive clinical experience and a defined clinical path to approval, we believe we have all the pieces to bring Sebacia’s breakthrough treatment for acne to market in Europe and the United States.”

The company’s light-activated microparticle treatment is delivered using a topical suspension designed to integrate with hair removal or pigmented lesion treatment laser systems – devices with which dermatologists are already likely familiar. The treatment has CE Mark clearance in Europe.

“We have been very impressed by the Sebacia team and are excited to join such a distinguished group of institutional life sciences investors,” John Dyett of Salem Partners added.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Pharmaceuticals Tagged With: sebacia

IN CASE YOU MISSED IT

  • Medtronic enrolls first patient in study for Onyx liquid embolic system
  • BD issues voluntary recall on certain Alaris infusion pump modules
  • Sequel Med Tech expects full twiist launch in the fall
  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS